10-K: MiNK Therapeutics Reports 2024 Results, Highlights Clinical Progress and Strategic Collaborations

MiNK Therapeutics details its 2024 financial results and provides an update on its clinical development programs, including agenT-797 and engineered iNKT cell therapies, along with strategic collaborations aimed at advancing cancer treatments.

Summary

• MiNK Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
• The company's lead product candidate, agenT-797, is in Phase 2 clinical trials for 2L gastric cancer and viral ARDS.
• A Phase 1 clinical trial of agenT-797 in solid tumor cancers showed durable clinical benefits and disease stabilization.
• MiNK-215 and MiNK-413, next-generation engineered iNKT programs, are in preclinical development with IND enabling activities underway for MiNK-215.
• A research collaboration with ImmunoScape aims to discover and develop next-generation TCR therapies against novel targets in solid tumors.
• The company reported a net loss of $10.8 million for 2024, compared to $22.5 million in 2023.
• As of December 31, 2024, MiNK had $4.6 million in cash and cash equivalents.
• The company believes its cash balance, plus anticipated funding from corporate transactions, will be sufficient to satisfy liquidity requirements for more than one year.
• Agenus owns approximately 55% of MiNK's outstanding common stock.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there's progress in clinical trials and strategic collaborations, the company's financial position raises concerns about its ability to continue as a going concern. The decrease in net loss and the belief that current funds will last over a year are positive, but the need for additional funding and the auditor's note of concern temper the outlook.

Positives

• AgenT-797 has shown encouraging activity in clinical trials, both as a monotherapy and in combination with other therapies.
• The company is advancing a pipeline of next-generation engineered iNKT programs.
• MiNK has a research collaboration with ImmunoScape to discover and develop next-generation TCR therapies.
• The company's net loss decreased significantly in 2024 compared to 2023.
• MiNK believes its current cash balance and anticipated funding will be sufficient to meet liquidity requirements for more than one year.

Negatives

• The company has incurred losses since inception and expects to continue incurring operating losses.
• MiNK's independent registered public accounting firm has included an explanatory paragraph relating to the company's ability to continue as a going concern in its report on the audited financial statements.
• The company is dependent on intellectual property licensed from third parties, including Agenus.
• Agenus owns a majority of MiNK's common stock and can exert control over matters subject to stockholder approval.

Risks

• The company may fail to raise additional capital, which could force it to delay, reduce, or eliminate certain projects.
• The success of the company is highly dependent on the success of agenT-797.
• Allogeneic iNKT cells represent a novel approach to immunotherapy, which may result in significant challenges to development, regulatory approval, and commercialization.
• The regulatory landscape that will govern any product candidates the company may develop is uncertain and may change.
• The company may experience difficulty in separating its resources from Agenus.
• The market price of the company's common stock may be volatile, which could result in substantial losses for investors.

Future Outlook

MiNK expects to continue incurring operating losses and negative cash flows in the future until it is able to generate sales and profits. The company believes its cash balance, plus anticipated funding from corporate transactions, will be sufficient to satisfy liquidity requirements for more than one year. The company plans to advance agenT-797 in viral ARDS through strategic collaborations and non-dilutive external financing into a randomized Phase 2 trial and expects to submit an IND to the FDA for MiNK-215 in 2025.

Management Comments

• Management continually monitors the Company's liquidity position and adjusts spending as needed in order to preserve liquidity.

Industry Context

The announcement reflects the ongoing efforts in the biopharmaceutical industry to develop novel cell therapies for cancer and immune-mediated diseases. MiNK's focus on allogeneic iNKT cell therapies aligns with the industry's interest in off-the-shelf solutions that can address the limitations of autologous cell therapies.

Comparison to Industry Standards

• The company's approach to cell therapy is comparable to companies like Allogene Therapeutics, Fate Therapeutics, and Atara Biotherapeutics, which are also developing allogeneic cell therapies.
• The company's focus on iNKT cells differentiates it from companies primarily focused on CAR-T or NK cell therapies, such as Gilead Sciences (Kite Pharma) and Celularity.
• The company's collaboration with ImmunoScape is similar to partnerships between other biotech companies to discover and develop novel TCR therapies.
• The company's efforts to develop a scalable manufacturing process for iNKT cells are in line with industry trends to reduce the cost and complexity of cell therapy manufacturing.

Related Party Transactions

• The company has a related party note outstanding as of December 31, 2024 of $5.0 million in principal plus accrued and unpaid interest of approximately $79,000 to Agenus.
• The company relies on Agenus for certain general and administrative support under an Amended and Restated Intercompany Services Agreement.
• The company's Chief Executive Officer is also an employee of Agenus.
• The company has a Master Services Agreement with Atlant Clinical Ltd., a subsidiary of Agenus, to provide clinical trial support services.
• The spouse of the company's CEO is a partner in the law firm of Wolf, Greenfield & Sachs, P.C., which provides legal services to the company.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will affect job security and opportunities.
• Patients: The success of the company's clinical trials will determine the availability of new treatment options for cancer and immune-mediated diseases.
• Collaborators: The company's ability to execute its strategy will impact the success of its collaborations with other companies and institutions.

Next Steps

• Advance agenT-797 in viral ARDS through strategic collaborations and non-dilutive external financing into a randomized Phase 2 trial.
• Submit an IND to the FDA for MiNK-215 in 2025.
• Continue the Phase 2 investigator-sponsored trial led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center.

Key Dates